GENEVA–( BUSINESS WIRE )–Regulatory News:
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceutical drugs, Inc. (NASDAQ: AERI, “Aerie”). This transaction helps bolster Alcon’s presence in the ophthalmic pharmaceutical space with its growing portfolio associated with commercial products and development pipeline.
“As we welcome the Aerie team to Alcon, we look forward to leveraging our expanding commercial footprint and expertise to bring Rocklatan ® plus Rhopressa ® in order to even more customers and their patients, ” said David Endicott, CEO of Alcon. “Alcon has a rich history in the ophthalmic pharmaceutical area rooted in a deep understanding of Eye Care Professionals. We are excited to add Aerie’s significant technical expertise in order to Alcon R& D, which enhances our own efforts to build a compelling portfolio of ophthalmic pharmaceuticals. ”
Through the particular transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0. 02%/0. 005% plus Rhopressa (netarsudil ophthalmic solution) 0. 02%, as well as AR-15512, the Phase 3 product candidate for dry eye disease. Alcon has also acquired a pipeline of ophthalmic pharmaceutical product candidates with the opportunity in order to leverage Aerie’s existing research and development capabilities.
The transaction complements Alcon’s expansion into the ophthalmic pharmaceutical space, including acquisitions associated with the exclusive U. S. commercialization rights for Simbrinza ® from Novartis in April 2021 and Eysuvis ® plus Inveltys ® from Kala Drugs, Inc. in May 2022.
Alcon intends to fully integrate Aerie into the business. As previously disclosed, the Company has used debt to fund the particular transaction for a total purchase consideration of approximately $930 million.
J. P. Morgan acted as Alcon’s financial advisor for the transaction, and Alcon’s legal advisor was Skadden, Arps, Slate, Meagher & Flom LLP. Goldman Sachs & Co. LLC and Lazard acted because Aerie’s financial advisors for the deal, and Aerie’s legal advisor was Fried, Frank, Harris, Shriver & Jacobson LLP.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight plus improve people’s lives. Our Surgical and Vision Care products touch the particular lives of more than 260 mil people inside over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our own more than 24, 000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye treatment. Learn more at www.alcon.com .
References
- Ophthalmology Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the safe harbor provisions from the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate, ” “intend, ” “commitment, ” “look forward, ” “maintain, ” “plan, ” “goal, ” “seek, ” “target, ” “assume, ” “believe, ” “project, ” “estimate, ” “expect, ” “strategy, ” “future, ” “likely, ” “may, ” “should, ” “will” plus similar references to future periods. Examples of forward-looking claims include, among others, statements all of us make regarding our liquidity, revenue, gross margin, operating margin, effective tax rate, foreign currency exchange movements, earnings per share, the plans and decisions relating to various capital expenditures, capital allocation priorities and other discretionary items such since the transformation program, market growth assumptions, our acquisition of Aerie, plus generally, our expectations concerning our future performance and the effects associated with the COVID-19 pandemic on our businesses.
Forward-looking statements are neither historical facts nor assurances of long term performance. Instead, they are based only on our current beliefs, expectations and presumptions regarding the potential of our business, future plans and strategies, along with other upcoming conditions. Because forward-looking statements relate to the future, they are subject in order to inherent uncertainties and risks that are difficult to predict such as: cybersecurity breaches or other disruptions of our information technology systems; compliance with data privacy, identity protection and information security laws; our own ability to comply with the particular US Foreign Corrupt Practices Act associated with 1977 as well as other applicable anti-corruption laws, particularly given that we have entered into a three-year Deferred Prosecution Agreement with the U. H. Department of Justice; the success in completing plus integrating strategic acquisitions; our ability to execute and achieve the expected benefits of our own transformation program; anticipated tax treatment, unforeseen liabilities, potential future capital expenses, revenues, expenses, earnings, synergies, economic performance, indebtedness, monetary condition, losses, future prospects, and company and management strategies with regard to the Aerie transaction; transaction costs associated with the Aerie transaction; the particular impact of a disruption in our global supply chain or important facilities; the effect of the COVID-19 pandemic because well since other viral or illness outbreaks; global and regional economic, economic, legal, taxes, political and social change; Russia’s war on Ukraine and the resulting worldwide response; the particular commercial success in our products and the ability in order to maintain plus strengthen our position inside our markets; the achievement of our own research and development efforts, including the ability to innovate in order to compete effectively; pricing pressure from changes in third party payor coverage plus reimbursement methodologies; ongoing industry consolidation; our ability to properly educate and train healthcare providers on this items; the impact of unauthorized importation of our products from countries with lower prices in order to countries along with higher prices; our reliance on outsourcing key business functions; modifications in inventory levels or even buying patterns of our own customers; the capability to attract and retain qualified personnel; our ability to service our debt obligations; the need for additional financing through the issuance associated with debt or equity; our ability to protect our intellectual property; the particular effects of litigation, which includes product liability lawsuits and governmental investigations; our capability to adhere to all laws to which usually we may become subject; impact of item recalls or even voluntary marketplace withdrawals; the implementation of our own enterprise resource planning system; the accuracy of our own accounting estimates and assumptions, including pension and other post-employment benefit plan obligations plus the carrying value associated with intangible assets; the ability to obtain regulatory clearance and approval of our items as well as conformity with any post-approval obligations, including high quality control of the manufacturing; legislative, tax and regulatory reform; the ability of Alcon Pharmaceuticals Ltd. to conform to its investment tax incentive agreement using the Swiss State Secretariat for Economic Affairs in Switzerland plus the Canton of Fribourg, Switzerland; our ability in order to manage environmental, social and governance matters to the satisfaction in our many stakeholders, some of which may have competing interests; the particular impact associated with being listed on two stock exchanges; the ability to declare and pay dividends; the different rights afforded to our shareholders as a Swiss corporation compared to the U. T. corporation; as well as the effect of maintaining or losing our own foreign private issuer status under U. S. securities laws.
Additional factors are usually discussed within our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more associated with these questions or dangers materialize, or even should underlying assumptions prove incorrect, actual results may vary materially through those anticipated. Therefore, you should not rely upon any of these forward-looking statements. Forward-looking statements inside this press release speak just as of the date of its filing, and we assume no obligation to update forward-looking claims as a result of new information, future events or otherwise.
Connect with us on